###begin article-title 0
Epithelial Neutrophil-Activating Peptide (ENA-78), Acute Coronary Syndrome Prognosis, and Modulatory Effect of Statins
###end article-title 0
###begin p 1
Conceived and designed the experiments: IZ AB GW JAS. Performed the experiments: IZ GW NC. Analyzed the data: IZ AB GW WH JW MAP. Contributed reagents/materials/analysis tools: IZ NC JAS. Wrote the paper: IZ AB GW NC SC MAP JAS.
###end p 1
###begin p 2
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 353 360 353 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5's</italic>
###xml 409 417 409 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 551 556 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 985 990 982 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 1429 1434 1423 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 1645 1650 1639 1644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 509 517 <span type="species:ncbi:9606">patients</span>
Endothelial inflammation with chemokine involvement contributes to acute coronary syndromes (ACS). We tested the hypothesis that variation in the chemokine gene CXCL5, which encodes epithelial neutrophil-activating peptide (ENA-78), is associated with ACS prognosis. We also investigated whether statin use, a potent modulator of inflammation, modifies CXCL5's association with outcomes and characterized the in vitro effect of atorvastatin on endothelial ENA-78 production. Using a prospective cohort of ACS patients (n = 704) the association of the CXCL5 -156 G>C polymorphism (rs352046) with 3-year all-cause mortality was estimated with hazard ratios (HR). Models were stratified by genotype and race. To characterize the influence of statins on this association, a statin*genotype interaction was tested. To validate ENA-78 as a statin target in inflammation typical of ACS, endothelial cells (HUVECs) were treated with IL-1beta and atorvastatin with subsequent quantification of CXCL5 expression and ENA-78 protein concentrations. C/C genotype was associated with a 2.7-fold increase in 3-year all-cause mortality compared to G/G+G/C (95%CI 1.19-5.87; p = 0.017). Statins significantly reduced mortality in G/G individuals only (58% relative risk reduction; p = 0.0009). In HUVECs, atorvastatin dose-dependently decreased IL-1beta-stimulated ENA-78 concentrations (p<0.0001). Drug effects persisted over 48 hours (p<0.01). CXCL5 genotype is associated with outcomes after ACS with potential statin modification of this effect. Atorvastatin lowered endothelial ENA-78 production during inflammation typical of ACS. These findings implicate CXCL5/ENA-78 in ACS and the statin response.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 202 205 202 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Hansson1">[1]</xref>
###xml 207 210 207 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Libby1">[2]</xref>
###xml 461 464 461 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Dinarello1">[3]</xref>
###xml 466 469 466 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Dinarello2">[4]</xref>
###xml 859 862 859 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-deLemos1">[5]</xref>
Endothelial inflammation plays a major role in the development and perpetuation of cardiovascular disease (CVD). The inflammatory process is complex, with various cellular mediators known to contribute [1], [2]. Multifunctional cytokines such as interleukin-1 (IL-1) play central roles in vascular inflammation. IL-1 produced from monocytes, macrophages, and other cells can initiate inflammation by inducing the production of chemokines from endothelial cells [3], [4]. Chemokines, in turn, propagate the process through recruitment and activation of additional cellular mediators of inflammation including neutrophils. This process is involved in many cardiovascular conditions including acute coronary syndrome (ACS). Moreover, previous work has established that monocyte chemokines such as monocyte chemoattractant protein-1 (MCP-1) are prognostic in ACS [5]. However, the role of neutrophil chemokines in ACS has not been well described.
###end p 4
###begin p 5
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 271 274 268 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Walz1">[6]</xref>
###xml 275 278 272 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Strieter1">[9]</xref>
###xml 308 313 305 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 391 396 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 460 464 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Damas1">[10]</xref>
###xml 465 469 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Damas2">[12]</xref>
###xml 561 566 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 748 752 745 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh1">[13]</xref>
###xml 899 907 <span type="species:ncbi:9606">patients</span>
CXCL5 (MIM *600324 a.k.a. epithelial neutrophil-activating peptide 78 or ENA-78) is a C-X-C chemokine that attracts and activates neutrophils. Furthermore, CXCL5 expression has been shown to be highly inducible in endothelial and vascular smooth muscle cells by IL-1beta [6]-[9]. Recent data have implicated CXCL5 and/or its receptors in congestive heart failure and ischemic stroke, making CXCL5 a candidate gene for other manifestations of CVD including ACS [10]-[12]. We previously identified a -156G>C (rs352046) single nucleotide polymorphism (SNP) in the CXCL5 promoter region to occur with high minor allele frequency in the general population and associate with both elevated plasma ENA-78 concentrations and leukocyte production of ENA-78 [13]. We therefore tested the primary hypothesis that this SNP is associated with 3-year all-cause mortality in a prospectively enrolled cohort of ACS patients.
###end p 5
###begin p 6
###xml 194 199 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Schwartz1">[14]</xref>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh2">[15]</xref>
###xml 491 496 491 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 612 617 612 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 722 727 722 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
Beyond testing this association, we also sought to describe potential associations with ACS therapies, namely statins, plausibly capable of influencing inflammation and outcome as a function of CXCL5 genotype. Statins improve outcomes in ACS in part through anti-inflammatory properties. [14]. We previously reported that basal endothelial ENA-78 production is modulated by atorvastatin [15]. Therefore, we also tested the hypothesis that statin treatment may modify the association between CXCL5 genotypes and outcomes in our ACS cohort. Finally, to offer insight into our epidemiological findings and validate CXCL5 as a potential candidate in statin pharmacogenetics, we tested whether atorvastatin treatment modulates CXCL5 expression and ENA-78 production from endothelial cells exposed to IL-1beta, a model of cardiovascular inflammation typical of ACS.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
Clinical Characteristics
###end title 8
###begin p 9
###xml 153 160 151 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003117-t001">Table 1</xref>
###xml 322 327 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 653 660 651 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003117-t001">Table 1</xref>
###xml 994 1001 992 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003117-t002">Table 2</xref>
###xml 9 16 <span type="species:ncbi:9606">patient</span>
###xml 76 81 <span type="species:ncbi:9606">women</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
###xml 858 866 <span type="species:ncbi:9606">patients</span>
The mean patient age was 61+/-12 years, and the cohort was comprised of 36% women and 79% Caucasians. Complete clinical characteristics are displayed in Table 1. The minor allele frequency for -156C was 17%. Genotype frequencies did not deviate from Hardy-Weinberg expectations. The patients were similar when compared by CXCL5 -156G>C genotype with the following exceptions: compared with G/G homozygotes, those with the C/C genotype were slightly younger, less likely to be Caucasian, had a greater prevalence of unstable angina as their ACS type, had higher admission DBP, had higher discharge HDL, and were less likely to be discharged on a statin (Table 1). G/C heterozygotes generally exhibited the above phenotypes in a fashion intermediate between G/G and C/C individuals. When baseline characteristics were compared by genotype in Caucasians alone, patients with the C/C genotype were older, but otherwise had no significantly different characteristics from the other genotype groups (Table 2).
###end p 9
###begin title 10
Baseline Characteristics.
###end title 10
###begin p 11
###xml 10 16 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 25 38 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8225;</sup>
###xml 47 59 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#167;</sup>
*n = 603; daggern = 594; double daggern = 565; section signn = 593; ACS = Acute coronary syndrome; MI = Myocardial infarction; LBB = Left bundle block; HTN = Hypertension; BMI = Body mass index; EF = Ejection fraction; SBP = Systolic blood pressure; DBP = Diastolic blood pressure; HDL = High density lipoprotein; LDL = Low density lipoprotein; PCI = Percutaneous coronary intervention; CABG = Coronary artery bypass graft.
###end p 11
###begin title 12
Baseline Characteristics in Caucasians.
###end title 12
###begin p 13
###xml 10 16 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 25 38 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8225;</sup>
###xml 47 59 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#167;</sup>
*n = 473; daggern = 464; double daggern = 436; section signn = 465; ACS = Acute coronary syndrome; MI = Myocardial infarction; LBB = Left bundle block; HTN = Hypertension; BMI = Body mass index; EF = Ejection fraction; SBP = Systolic blood pressure; DBP = Diastolic blood pressure; HDL = High density lipoprotein; LDL = Low density lipoprotein; PCI = Percutaneous coronary intervention; CABG = Coronary artery bypass graft.
###end p 13
###begin title 14
Main Effect of CXCL5 Genotype on ACS Outcomes
###end title 14
###begin p 15
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 325 334 325 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g001">Figure 1A</xref>
###xml 445 454 445 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g001">Figure 1B</xref>
###xml 621 630 621 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g002">Figure 2A</xref>
###xml 696 705 696 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g002">Figure 2B</xref>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
CXCL5 -156 G>C genotype was significantly associated with 3-year all-cause mortality in ACS patients. The death rate was 10% in G/G, 13% in G/C, and 29% in C/C individuals (p = 0.005). C/C genotype was associated with a hazard ratio of 3.09 (95% confidence interval [CI], 1.54-6.19; p = 0.002) compared to G/C+G/G genotypes (Figure 1A). This effect remained significant when Caucasians alone were analyzed (HR 4.0, 95%CI 1.45-11.05; p = 0.008) (Figure 1B). The increased risk of mortality remained significant after adjustment for clinical covariates both in the overall population (HR 2.65, 95%CI 1.19-5.87; p = 0.017) (Figure 2A) and in Caucasians alone (HR 3.25, 95%CI 1.04-10.13; p = 0.043) (Figure 2B).
###end p 15
###begin title 16
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
Kaplan Meier estimates for all-cause mortality by CXCL5 -156 G>C genotype.
###end title 16
###begin p 17
Panel A represents the overall population; panel B represents the Caucasians only.
###end p 17
###begin title 18
Adjusted hazard ratio and 95% confidence intervals for all-cause mortality by genotype.
###end title 18
###begin p 19
Top panel is overall population (p = 0.017) and bottom panel is Caucasians only (p = 0.043). Models adjusted for age, race, sex, ACS type, revascularization strategy, history of diabetes, and history of heart failure.
###end p 19
###begin title 20
Statin Interaction
###end title 20
###begin p 21
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 396 404 396 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g003">Figure 3</xref>
###xml 809 817 809 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g003">Figure 3</xref>
###xml 473 481 <span type="species:ncbi:9606">Patients</span>
###xml 590 598 <span type="species:ncbi:9606">patients</span>
We identified an interaction between discharge statin therapy and CXCL5 -156 G>C genotype (p = 0.09). Individuals with the G/G genotype who were prescribed a statin at hospital discharge had a significantly lower 3-year all-cause mortality rate compared to those who did not receive a statin at hospital discharge (absolute risk reduction 10.8%; relative risk reduction [RRR] 58.4%; p = 0.0009) (Figure 3). Statin benefit was diminished in the G/C and C/C genotype groups. Patients with the G/C genotype experienced a non-significant RRR of 25% when discharged on statins (p = 0.48), while patients with the C/C genotype prescribed statin therapy had a numerically greater, although not significant, mortality rate compared to those not prescribed statin therapy (35.3% versus 21.4%, respectively; p = 0.46) (Figure 3).
###end p 21
###begin title 22
###xml 74 82 <span type="species:ncbi:9606">patients</span>
All-cause mortality rate by genotype among statin-treated and non-treated patients.
###end title 22
###begin p 23
*p = 0.0009., daggerp = 0.48; double daggerp = 0.46.
###end p 23
###begin title 24
Effect of Atorvastatin on IL-1beta-induced ENA-78 Production from Endothelial Cells
###end title 24
###begin p 25
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 83 91 83 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 279 287 271 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g004">Figure 4</xref>
###xml 431 439 416 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g005">Figure 5</xref>
To validate CXCL5/ENA-78 as an endothelial target for statins, we utilized a HUVEC in vitro model of cardiovascular inflammation. There were no significant differences in HUVEC viability between control conditions and any dose of atorvastatin ranging from 1 microM to 50 microM (Figure 4). IL-1beta increased ENA-78 production by nearly 60-fold relative to constitutive concentrations (4075+/-296 pg/mg vs. 69+/-7 pg/mg; p<0.0001; Figure 5). Treatment with atorvastatin attenuated this effect by 38%, 70%, 78%, 93%, and 99% in the five atorvastatin dose groups (p<0.001 for all comparisons vs. IL-1beta).
###end p 25
###begin title 26
Cell viability of HUVECs cultured for 24 hours with atorvastatin.
###end title 26
###begin p 27
Data are presented as mean+/-SEM of 3 experiments. *p<0.0001. AT, atorvastatin.
###end p 27
###begin title 28
Atorvastatin attenuates IL-1beta-induced ENA-78 production in a dose-dependent fashion.
###end title 28
###begin p 29
Data are presented as mean+/-SEM of 4 experiments. * p<0.0001 vs. IL-1beta, daggerp = NS vs. control. AT, atorvastatin.
###end p 29
###begin p 30
###xml 140 148 134 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g006">Figure 6</xref>
The time-dependent course of ENA-78 changes relative to control in response to IL-1beta and atorvastatin/IL-1beta co-treatment are shown in Figure 6. Atorvastatin's time effect was significant at 24 hours and most pronounced at 48 hours. Specifically, atorvastatin attenuated IL-1beta stimulated production of ENA-78 at 4, 12, 24, and 48 hours by 0%, 30%, 59% (p = 0.01), and 76% (p = 0.009), respectively.
###end p 30
###begin title 31
Atorvastatin attenuates ENA-78 production over time.
###end title 31
###begin p 32
Levels are relative to baseline (0 hour) for each condition. Data are presented as mean+/-SEM of 4 experiments. *p</=0.01. -o-, IL-1beta stimulation+atorvastatin 10 microM; -*-, IL-1beta stimulation alone; AT, atorvastatin.
###end p 32
###begin p 33
###xml 372 380 365 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g007">Figure 7</xref>
To determine whether atorvastatin effects were dependent on HMG-CoA reductase inhibition, HUVECs were cultured with IL-1beta and atorvastatin 10 microM in the presence or absence of mevalonate. To assess whether downstream products of mevalonate biosynthesis are implicated in the drug effect, conditions also included cultures in the presence or absence of FPP and GGPP (Figure 7). Consistent with the previous experiments, atorvastatin significantly attenuated IL-1beta-stimulated ENA-78 production (3181+/-407 pg/mg vs. 1054+/-234 pg/mg; p<0.001). Co-treatment with mevalonate and FPP reversed the effect of atorvastatin (p = NS vs. IL-1beta), and GGPP partially reversed the effect of atorvastatin (p = 0.05 vs. IL-1beta).
###end p 33
###begin title 34
Atorvastatin effects on ENA-78 are reversed by mevalonate and its downstream metabolites.
###end title 34
###begin p 35
Data are presented as mean+/-SEM of 10 experiments. *p<0.001 and daggerp = 0.05 compared to IL-1beta stimulation alone. AT, atorvastatin; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; MEV, mevalonate.
###end p 35
###begin p 36
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 116 121 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 254 259 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 272 280 266 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003117-g008">Figure 8</xref>
Atorvastatin significantly lowered constitutive expression of CXCL5 (p<0.005), while IL-1beta significantly induced CXCL5 expression in HUVECs at 24 hours (p<0.0001). However, pre-treatment of HUVECs with atorvastatin did not blunt IL-1beta induction of CXCL5 expression (Figure 8).
###end p 36
###begin title 37
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
CXCL5 expression is modulated by atorvastatin and IL-1beta.
###end title 37
###begin p 38
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 64 66 64 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 173 178 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
(A) Gel electrophoresis of CXCL5 and GAPDH PCR products; (B) Log10 relative quantification of CXCL5 modulated by atorvastatin, IL-1beta, and their combination normalized to GAPDH (N = 2 experiments). *P<0.005, daggerP<0.0001. AT, atorvastatin.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
###xml 464 472 <span type="species:ncbi:9606">patients</span>
In the current analysis, we demonstrate that a common promoter polymorphism in the ENA-78 gene (CXCL5) is associated with 3-year all-cause mortality in ACS patients, adding further support for a role of neutrophil chemoattractants in acute ischemic syndromes. Even after adjustment for age, sex, ACS type, revascularization strategy, heart failure, and diabetes, patients with two copies of the -156C variant allele were at 2.7-fold higher risk for mortality than patients with at least one copy of the -156G wild-type allele. The overall death rates for G/G, G/C, and C/C individuals were 10%, 13%, and 29%, respectively.
###end p 40
###begin p 41
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Chello1">16</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Sugano1">20</xref>
###xml 1019 1023 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Smith1">[21]</xref>
###xml 1129 1133 1129 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Smith1">[21]</xref>
###xml 1521 1529 1521 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1596 1603 1596 1603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1603 1607 1603 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Kiener1">[22]</xref>
###xml 1799 1804 1799 1804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 1937 1941 1937 1941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh1">[13]</xref>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 1099 1107 <span type="species:ncbi:9606">patients</span>
###xml 1228 1236 <span type="species:ncbi:9606">patients</span>
###xml 1729 1737 <span type="species:ncbi:9606">patients</span>
###xml 1977 1985 <span type="species:ncbi:9606">patients</span>
Importantly, we also demonstrated a pharmacogenetic relationship between CXCL5 genotypes and discharge statin use. G/G patients experienced a significant RRR of 58% in all-cause mortality; G/C heterozygotes experienced a non-significant reduction of 25%; and C/C homozygotes experienced a non-significant increase of 39%. Our findings of an association between discharge statin use and mortality, as a function of CXCL5 genotype, is an important extension of previous work. Several lines of evidence suggest that part of the cardioprotective effect of statins is related to their ability to modulate neutrophil function by various mechanisms, including reduced production of neutrophil chemokines 16-20. Our findings that the absolute mortality rate was numerically higher in C/C homozygotes discharged on a statin compared with C/C homozygotes not discharged on a statin is congruent with findings regarding the influence of statins on NAP-2, a neutrophil-activating chemokine exhibiting over 50% homology with ENA-78 [21]. Smith and colleagues demonstrated elevated NAP-2 plasma concentrations in patients with unstable angina [21]. However, while aspirin lowered plasma NAP-2, statin treatment stimulated NAP-2 production in patients, peripheral blood mononuclear cells, and platelets. This pro-inflammatory effect has also been observed by others; Kiener and colleagues demonstrated that some, but not all, statins stimulate monocyte production of pro-inflammatory cytokines including IL-8 (22% homology with ENA-78) in vitro and increase influx of leukocyte subtypes (including neutrophils) in vivo[22]. Therefore, while there is a strongly beneficial effect of statin therapy in the general population, some subsets of ACS patients may not derive such benefit. We have previously demonstrated CXCL5 -156C carriers exhibit significantly greater plasma concentrations of ENA-78 and greater ENA-78 production from cultured leukocytes [13]. Therefore, it is conceivable that patients with the -156 C/C genotype may simultaneously represent a population at higher risk for ACS mortality that experiences little, if any, benefit from discharge statin therapy. The exact mechanism of this observation warrants further investigation.
###end p 41
###begin p 42
###xml 58 66 58 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 249 252 246 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Walz1">[6]</xref>
###xml 254 257 251 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Schmouder1">[7]</xref>
###xml 259 262 256 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Strieter1">[9]</xref>
###xml 880 884 874 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Cannon1">[23]</xref>
###xml 885 889 879 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Patti1">[25]</xref>
In addition to our epidemiological analyses, we performed in vitro experiments and showed that CXCL5/ENA-78 is an endothelial target for statins. We corroborated previous work which showed ENA-78 is highly inducible by IL-1beta in endothelial cells [6], [7], [9]. In the current experiments, atorvastatin modulated IL-1beta-mediated ENA-78 production in a dose- and time-specific manner, through pathways involving HMG-CoA reductase and prenylation proteins. The drug effect began as early as 12 hours after stimulation and persisted out to 48 hours with no signs of diminishment. It has been hypothesized that statins exhibit early anti-inflammatory effects that may explain their benefit in acute manifestations of CVD (e.g., ACS). Furthermore, it has been shown that short-term statin treatment in certain cardiovascular settings result in demonstrable improvement in outcomes [23]-[25]. Our data suggest that early and persistent inhibition of IL-1beta-induced endothelial ENA-78 production should be considered part of the spectrum of statin pleiotropism, and may represent an important mechanism of statin benefit in ACS and conditions marked by neutrophil involvement.
###end p 42
###begin p 43
###xml 598 606 598 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 831 835 831 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Brown1">[26]</xref>
###xml 836 840 836 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Park1">[29]</xref>
While postulated to be independent of LDL lowering, the anti-inflammatory effects of statins are thought to result from HMG-CoA reductase inhibition and/or inhibited production of prenylation precursors, such as FPP and GGPP. Our findings support this body of evidence in that atorvastatin's modulatory effect on ENA-78 was reversed by the addition of mevalonate and FPP, and partially reversed by GGPP. Previous studies have explored the effects of FPP and GGPP on statin responses, with the hope of elucidating the contribution of prenylation pathways on drug effects. Reversal of statin effects in vitro by the addition of FPP and GGPP implicate the Ras and Rho signaling pathways. Previous studies have shown that either Ras or Rho signaling may be involved in the statin effect, depending on the specific drug response tested [26]-[29].
###end p 43
###begin p 44
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 537 541 534 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh2">[15]</xref>
###xml 622 627 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 991 995 985 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Furman1">[30]</xref>
###xml 1202 1206 1193 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Lindholm1">[31]</xref>
###xml 1208 1212 1199 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Mandey1">[32]</xref>
###xml 1687 1692 1663 1668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 1896 1901 1869 1874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
While we showed atorvastatin to lower endothelial ENA-78 protein production under pro-inflammatory conditions, we also investigated whether atorvastatin lowered CXCL5 expression. We found a significant reduction in basal CXCL5 expression with atorvastatin treatment that was not observed for conditions with IL-1beta stimulation. Nonetheless, we have previously shown basal endothelial ENA-78 protein production to be reduced by atorvastatin in a dose-dependent fashion, and currently extend this observation to a pro-inflammatory state [15]. There are several possible reasons for the disparate impact of atorvastatin on CXCL5 expression in non-stimulated and stimulated conditions. Firstly, in a pro-inflammatory state (such as that induced by IL-1beta), the predominant statin effect may be post-transcriptional in nature. Similar findings have been reported for the effect of rosuvastatin on MMP-7 production and expression whereby protein production but not gene expression was lowered [30]. A second explanation can be found from recent studies that implicate geranylgeranylation as an important homeostatic mechanism in IL-1beta secretion from macrophages and peripheral blood mononuclear cells [31], [32]. Specifically, it was demonstrated that inhibition of isoprenoid production with statins led to upregulation of IL-1beta. This effect was more pronounced upon addition of exogenous IL-1beta (as in our experiments) suggesting that depletion of isoprenoids by statins shuts off the IL-1beta negative feedback loop. As such, one can speculate that co-treatment of HUVECs with IL-1beta and atorvastatin in our experiments may have potentiated IL-1beta autocrine activity. Since CXCL5 is highly inducible by IL-1beta in HUVECs, the preponderant drug effect manifested as a reduction of ENA-78 protein concentrations (presumable through a post-transcriptional mechanism) with no impact on CXCL5 expression.
###end p 44
###begin p 45
###xml 449 454 449 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 551 555 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh1">[13]</xref>
###xml 574 579 574 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 866 870 866 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOS3</italic>
###xml 1031 1035 1031 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Haller1">[33]</xref>
###xml 1037 1041 1037 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh3">[34]</xref>
###xml 1100 1105 1100 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 1837 1841 1837 1841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Muhlestein1">[35]</xref>
###xml 1860 1868 1860 1868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1910 1915 1910 1915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 2397 2402 2397 2402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 2497 2505 2497 2505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2661 2666 2661 2666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
###xml 1517 1525 <span type="species:ncbi:9606">patients</span>
###xml 1790 1798 <span type="species:ncbi:9606">patients</span>
There are several limitations to our analysis. Because of the epidemiological nature of the cohort study, data on white blood cell counts and differentials were unavailable. Therefore, the effect of these parameters on clinical endpoints in our population could not be directly tested. Along these lines, blood samples were not available to directly quantify ENA-78 protein concentrations in our patients. Nonetheless, we have previously shown that CXCL5 genotype is a predictor of circulating ENA-78 concentrations and leukocyte production of ENA-78 [13]. Furthermore, the CXCL5 genotype may in fact be a more stable marker of ACS risk than circulating ENA-78 concentrations since protein concentrations are more likely to be influenced by multiple stress-related factors. We have, in fact, shown this to be the case whereby endothelial nitric oxide (NO) synthase (NOS3) genotype was robustly associated with arterial stiffness, while circulating surrogate markers of NO activity (serum superoxide dismutase and nitrite) were not [33], [34]. We noted an interaction between discharge statin use and CXCL5 genotype on outcomes. Because we did not have drug-specific information, we could not determine if this effect was differential influenced by the specific statin used, or the type of statin (i.e., hydrophilic vs. lipophilic); nor would we likely have the power to conduct such an analysis if the data were available. We also do not have information on the persistence of discharge statin use over time in these patients. Additionally, because of the small sample size for this subgroup analysis, there is a possibility of a false positive finding between genotype and discharge statin use. Nonetheless, others have estimated persistence of discharge statin use to be nearly 80% among patients similar in characteristics to our own [35]. In addition, our in vitro endothelial experiments validated ENA-78/CXCL5 as an endothelial target of statin action in an inflammatory environment typical of ACS, adding biological plausibility to our epidemiological finding. Finally, because of the lack of granularity in the Social Security Administration Death Master File, the exact cause of mortality could not be determined. This is a known limitation of epidemiologic data and further analyses in independent cohorts are warranted. Despite these limitations, our data suggest that the ENA-78 gene, CXCL5, is associated with post-ACS all-cause mortality and is an endothelial target of atorvastatin in vitro. Whether ENA-78 modulation by statins is a central mediator of drug benefit in ACS is unknown. However, our findings strongly suggest a role of ENA-78 and CXCL5 genetic variants as determinants of CVD and drug response.
###end p 45
###begin title 46
Methods
###end title 46
###begin title 47
Acute Coronary Syndrome Cohort and Gene/SNP Selection
###end title 47
###begin p 48
###xml 99 103 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Lanfear1">[36]</xref>
###xml 628 632 628 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Braunwald1">[37]</xref>
###xml 1233 1237 1233 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh4">[38]</xref>
###xml 1239 1244 1239 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 1276 1284 1276 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a priori</italic>
###xml 1394 1398 1394 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Kruk1">[39]</xref>
###xml 1399 1403 1399 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Takeshita1">[41]</xref>
###xml 1531 1535 1531 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh2">[15]</xref>
###xml 1708 1715 1708 1715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1715 1719 1715 1719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh1">[13]</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 676 683 <span type="species:ncbi:9606">patient</span>
###xml 1149 1161 <span type="species:ncbi:9606">participants</span>
###xml 1163 1175 <span type="species:ncbi:9606">Participants</span>
The methods of accrual and adjudication for this prospective cohort have been previously described [36]. Briefly, patients with a confirmed ACS were enrolled from two Kansas City hospitals. Myocardial infarction (MI) was defined by elevated troponin level in combination with chest pain symptoms or electrocardiographic findings (ST-segment elevation or non-ST-segement elevation) consistent with MI. Unstable angina was defined by a negative troponin level and any one of the following: new-onset angina (<2 months), prolonged angina (>20 minutes) at rest, recent worsening angina, or angina that occurred within 2 weeks of MI [37]. Demographic information was obtained from patient interviews during hospital admission. Medical history, medication history, laboratory values, and inpatient treatment during the ACS hospitalization were obtained from chart abstractions. The Social Security Administration Death Master File () was queried approximately once yearly to obtain three-year all-cause mortality assessment. The study was approved by the institutional review boards of both institutions and written informed consent was obtained from all participants. Participants were genotyped according to previously published methods [38]. CXCL5 (MIM 600324) was chosen as our a priori candidate gene based on 1) the known role of the neutrophil pathway in cardiovascular diseases including ACS [39]-[41], and 2) our previously published data demonstrating atorvastatin to significantly lower basal production of endothelial ENA-78 [15]. The -156G>C SNP (rs352046) was chosen as our candidate SNP because of our previous work demonstrating this SNP to be associated with variable ENA-78 protein concentration in vivo[13].
###end p 48
###begin title 49
In Vitro Endothelial Experiments
###end title 49
###begin title 50
Cell Culture and Reagents
###end title 50
###begin p 51
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh2">[15]</xref>
###xml 217 218 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human umbilical vein endothelial cells (HUVECs) (Lonza Walkersville, Inc., Walkersville, MD) were cultured as previously described [15]. Briefly, HUVECs between passes three and four were seeded at a density of 2.5x104 cells per cm2 and cultured to 80% confluence with endothelial cell growth-supplemented medium. Once confluent, media were changed to serum free endothelial basal media for 24 hours prior to treatment after which basal media supplemented to 2% FBS concentration was used.
###end p 51
###begin p 52
Treatments consisted of atorvastatin calcium (LKT Laboratories Inc., St. Paul, MN) 1-50 microM dissolved in dimethyl sulfoxide (DMSO). IL-1beta, mevalonate, farnesyl pyrophosphate (FPP), and geranylgeranyl pyrophosphate (GGPP; all from Sigma-Aldrich, St. Louis, MO) were all dissolved in molecular grade water and used at concentrations of 2 ng/ml, 250 microM, 5 microM, and 5 microM respectively. All final DMSO concentrations were less then 0.1%.
###end p 52
###begin title 53
Treatments
###end title 53
###begin p 54
Cell viability was assessed by trypan blue staining. In experiments investigating the impact of atorvastatin dose on ENA-78 production, HUVECs were pre-treated with atorvastatin followed by addition of IL-1beta two hours later. After dose-ranging studies were performed, the time-dependent effects of atorvastatin were investigated at 0, 4, 12, 24, and 48 hours. In separate experiments, cells were cultured with IL-1beta and atorvastatin in the presence or absence of mevalonate, FPP, and GGPP to determine whether atorvastatin inhibition of ENA-78 production was dependent on HMG-CoA reductase inhibition and subsequent downstream pathways. Cell culture supernates for all experiments were stored at -20degreesC until analysis, which was performed within seven days.
###end p 54
###begin title 55
Protein Quantification and Gene Expression
###end title 55
###begin p 56
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Zineh2">[15]</xref>
###xml 628 633 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 712 717 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 877 882 873 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 884 909 880 905 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5-CGGGAAGGAAATTTGTCTTGA-3</named-content>
###xml 911 936 907 932 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5-AGCTTAAGCGGCAAACATAGG-3</named-content>
###xml 942 947 938 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 949 974 945 970 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5-AAAATCAAGTGGGGCGATGCT-3</named-content>
###xml 976 1000 972 996 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5-GCCAGGGGTGCTAAGCAGTT-3</named-content>
###xml 1016 1021 1012 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 1026 1031 1022 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
ENA-78 concentrations were measured and normalized to total protein content using cytometric immunofluorescence as previously described [15]. Ribonucleic acid (RNA) was isolated using a commercial kit (RNeasy mini kit, Qiagen Inc., Valencia, CA). Complementary deoxyribonucleic acid (cDNA) conversion was performed by high capacity cDNA reverse transcription (Applied Biosystems, Foster City, CA) per protocol using roughly 2 microg of total RNA. RNA quality was assessed by absorbance (Nanodrop, Nanodrop Technologies, Wilmington, DE). Real-time reverse-transcription PCR (RT-PCR) was performed using primer and probe sets for CXCL5 normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Taqman Gene Expression Assays, Applied Biosystems Inc.). Relative quantification was verified by gel electrophoresis of PCR products using exonic primers for CXCL5 (5-CGGGAAGGAAATTTGTCTTGA-3; 5-AGCTTAAGCGGCAAACATAGG-3) and GAPDH (5-AAAATCAAGTGGGGCGATGCT-3; 5-GCCAGGGGTGCTAAGCAGTT-3). PCR for both CXCL5 and GAPDH were performed in parallel reactions using the following conditions: 95degreesC for 2 minutes; 35 cycles of 95degreesC for 30 seconds, 59degreesC for 30 seconds, and 72degreesC for 30 seconds; followed by 7 minutes of elongation at 72degreesC.
###end p 56
###begin title 57
Statistical Analyses
###end title 57
###begin title 58
ACS Cohort
###end title 58
###begin p 59
###xml 610 622 <span type="species:ncbi:9606">participants</span>
Baseline characteristics were compared by ANOVA, student's t-test or chi-square tests as appropriate. Allele frequencies were calculated by allele counting and deviations from Hardy-Weinberg equilibrium were tested by chi-square. Death rates were compared by chi-square or Fisher's exact tests. To minimize multiple testing and maximize statistical power, one mode of inheritance was tested (recessive) only after visual inspection of survival curves for all three genotype groups. We had 80% power to detect a hazard ratio of 1.57 under the tested recessive model of inheritance, given our sample size of 704 participants and a minor allele frequency of 17%.
###end p 59
###begin p 60
###xml 336 341 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 833 837 829 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Lee1">[42]</xref>
Cox proportional hazards models were developed that included the following pre-specified covariates: age, sex, ACS type (ST elevation MI, non ST elevation MI, or unstable angina), coronary revascularization strategy (medical management, percutaneous coronary intervention, or coronary artery bypass graft), heart failure, diabetes, and CXCL5 genotype. Additionally, interactions between genotype and discharge statin use were assessed in the models. All models were conducted in the overall population and separately by race to minimize confounding by population stratification. Survival plots were generated by the Kaplan-Meier technique. The statin*genotype interaction term was considered significant if p<0.1 (two-sided) since multiplicative interaction testing is generally not powered to detect significance at an alpha = 0.05 [42]. In all other analyses, p<0.05 was considered significant. SAS version 9.1 was used for all analyses.
###end p 60
###begin title 61
In Vitro Experiments
###end title 61
###begin p 62
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL5</italic>
###xml 326 339 326 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;&#916;Ct</sup>
###xml 347 351 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003117-Livak1">[43]</xref>
ENA-78 protein concentrations and CXCL5 gene expression levels were compared for all conditions by one-way ANOVA with Tukey correction for multiple comparisons. An independent t-test was used to compare treatment differences at each time point in the time-course studies. Relative CXCL5 gene expression was determined by the 2-DeltaDeltaCt method [43]. A p-value<0.05 was considered significant. Statistical analyses were performed with SPSS software, version 11.5 (SPSS Inc., Chicago, USA). The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
###end p 62
###begin title 63
References
###end title 63
###begin article-title 64
Inflammation, atherosclerosis, and coronary artery disease.
###end article-title 64
###begin article-title 65
Inflammation and atherosclerosis.
###end article-title 65
###begin article-title 66
Interleukin-1 and interleukin-1 antagonism.
###end article-title 66
###begin article-title 67
Biologic basis for interleukin-1 in disease.
###end article-title 67
###begin article-title 68
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.
###end article-title 68
###begin article-title 69
Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8.
###end article-title 69
###begin article-title 70
###xml 65 70 <span type="species:ncbi:9606">human</span>
Epithelial-derived neutrophil-activating factor-78 production in human renal tubule epithelial cells and in renal allograft rejection.
###end article-title 70
###begin article-title 71
###xml 128 133 <span type="species:ncbi:9606">human</span>
Effect of 15-deoxy-delta12,14-prostaglandin J2 on IL-1beta-induced expression of epithelial neutrophil-activating protein-78 in human endothelial cells.
###end article-title 71
###begin article-title 72
The detection of a novel neutrophil-activating peptide (ENA-78) using a sensitive ELISA.
###end article-title 72
###begin article-title 73
CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes.
###end article-title 73
###begin article-title 74
The level of chemokine CXCL5 in the cerebrospinal fluid is increased during the first 24 hours of ischaemic stroke and correlates with the size of early brain damage.
###end article-title 74
###begin article-title 75
###xml 71 76 <span type="species:ncbi:9606">human</span>
Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure.
###end article-title 75
###begin article-title 76
CXCL5 gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78).
###end article-title 76
###begin article-title 77
The case for intensive statin therapy after acute coronary syndromes.
###end article-title 77
###begin article-title 78
Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors.
###end article-title 78
###begin article-title 79
Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery.
###end article-title 79
###begin article-title 80
Statins inhibit neutrophil infiltration in skeletal muscle reperfusion injury.
###end article-title 80
###begin article-title 81
Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study.
###end article-title 81
###begin article-title 82
Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin.
###end article-title 82
###begin article-title 83
Polymorphonuclear leukocytes may impair endothelial function: results of crossover randomized study of lipid-lowering therapies.
###end article-title 83
###begin article-title 84
Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation.
###end article-title 84
###begin article-title 85
Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.
###end article-title 85
###begin article-title 86
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
###end article-title 86
###begin article-title 87
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
###end article-title 87
###begin article-title 88
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
###end article-title 88
###begin article-title 89
The Rac and Rho hall of fame: a decade of hypertrophic signaling hits.
###end article-title 89
###begin article-title 90
###xml 45 50 <span type="species:ncbi:9606">human</span>
Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene.
###end article-title 90
###begin article-title 91
Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity.
###end article-title 91
###begin article-title 92
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 43 48 <span type="species:ncbi:9606">human</span>
Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis.
###end article-title 92
###begin article-title 93
###xml 40 45 <span type="species:ncbi:9606">human</span>
Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability.
###end article-title 93
###begin article-title 94
Simvastatin stimulates macrophage interleukin-1beta secretion through an isoprenylation-dependent mechanism.
###end article-title 94
###begin article-title 95
A role for geranylgeranylation in interleukin-1beta secretion.
###end article-title 95
###begin article-title 96
###xml 97 105 <span type="species:ncbi:9606">children</span>
Serum superoxide dismutase activity and nitric oxide do not correlate with arterial stiffness in children with type 1 diabetes mellitus.
###end article-title 96
###begin article-title 97
###xml 61 69 <span type="species:ncbi:9606">children</span>
NOS3 polymorphisms are associated with arterial stiffness in children with type 1 diabetes.
###end article-title 97
###begin article-title 98
Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality.
###end article-title 98
###begin article-title 99
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.
###end article-title 99
###begin article-title 100
Unstable angina. A classification.
###end article-title 100
###begin article-title 101
Development and cross-validation of sequencing-based assays for genotyping common polymorphisms of the CXCL5 gene.
###end article-title 101
###begin article-title 102
###xml 76 84 <span type="species:ncbi:9606">Patients</span>
Association of Non-Specific Inflammatory Activation With Early Mortality in Patients With ST-Elevation Acute Coronary Syndrome Treated With Primary Angioplasty.
###end article-title 102
###begin article-title 103
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease.
###end article-title 103
###begin article-title 104
Systemic inflammatory responses in acute coronary syndrome: increased activity observed in polymorphonuclear leukocytes but not T lymphocytes.
###end article-title 104
###begin article-title 105
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study.
###end article-title 105
###begin article-title 106
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
###end article-title 106
###begin p 107
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The University of Florida has filed a patent for CXCL5 polymorphisms and ENA-78 concentrations as diagnostic and prognostic tools with Dr. Zineh as a co-inventor. No final decision has been rendered.
###end p 107
###begin p 108
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by American Heart Association Florida/Puerto Rico Affiliate Scientist Development Grant 0435278B, NIH C06 Grant RR17568, and NIH P50 Grant HL077113. The sponsors did not have a role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.
###end p 108

